Multiple Myeloma
Multiple myeloma is a cancer of antibody-producing plasma cells in bone marrow. Abnormal cells and proteins can weaken bones, impair kidney function, suppress normal blood production and increase infection risk.
Lenalidomide Capsules
10mg
Lenalidomide 10mg hard capsules, used in the management of multiple myeloma and myelodysplastic syndromes. A thalidomide analogue and immunomodulator.
Key points
- Persistent bone pain, anaemia, kidney impairment, high calcium or recurrent infections can prompt testing but do not confirm myeloma alone.
- Diagnosis and treatment planning use blood, urine, marrow, imaging and genetic findings.
- Treatment combines medicine classes according to fitness, transplant eligibility, disease biology and prior therapy.
The catalogue cannot diagnose myeloma or define a regimen; individual agents require haematology supervision, combinations and supportive care.
How is myeloma investigated?
Testing looks for a monoclonal protein, abnormal light chains and marrow plasma cells, then assesses calcium, kidneys, anaemia and bone lesions. Related precursor conditions may be monitored rather than treated, so diagnostic criteria matter.
What shapes treatment?
Lenalidomide, cyclophosphamide or melphalan may form parts of selected plans; none is a stand-alone catalogue choice. Bone protection, infection prevention and kidney-aware supportive care belong within oncology support.
When to seek urgent care
Seek urgent help for new leg weakness, numbness or bladder or bowel loss; sudden severe bone pain after minor movement; confusion, dehydration, markedly reduced urine, chest pain, breathing difficulty or fever during treatment.